MPDL3280A for Non-Small Cell Lung Cancer

Roy S. Herbst, MD, PhD
Published Online: June 12, 2013


Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).

Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.

These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.

Clinical Pearls



  • MPDL3280A produced a 21% response rate for patients with multiple solid tumors, including NSCLC
  • MPDL3280A had an acceptable toxicity profile, with only a few patients having immune-related events
  • These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC


<<< View all coverage from the 2013 ASCO Meeting

Related Articles
Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with a ghrelin agonist, two randomized trials showed.
Almost 60% of patients with advanced non–small cell lung cancer (NSCLC) had tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab
A randomized, open-label study is currently under way to test the safety and efficacy of the novel immunoadjuvant, Multikine, in patients with head and neck cancer.
Therapeutic options available for the treatment of metastatic non-small cell lung cancer (NSCLC) include cytotoxic chemotherapies and targeted therapies.
JTT Articles
Q & A With Dr. Sunil Verma: Targeted Treatments for HER2-Positive Breast Cancer
CD19-Targeted Agents Continue to Show Positive Outcomes
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.